Snowden Capital Advisors’s Genmab GMAB Stock Holding History

Snowden Capital Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$277K	Buy	10,336 +2,275	+28%	+$68.2K	0.01%	1066
2025 Q4	$248K	Buy	8,061 +1,290	+19%	+$40.2K	0.01%	1123
2025 Q3	$208K	Buy	+6,771	New	+$165K	0.01%	1181
2024 Q2	–	Sell	-6,861	Closed	-$205K	–	1203
2024 Q1	$205K	Buy	+6,861	New	+$202K	0.01%	1123
2023 Q4	–	Sell	-5,721	Closed	-$202K	–	1122
2023 Q3	$202K	Buy	5,721 +155	+3%	+$5.91K	0.01%	1019
2023 Q2	$212K	Buy	5,566 +158	+3%	+$6.3K	0.01%	1085
2023 Q1	$204K	Buy	5,408 +633	+13%	+$24.3K	0.01%	1076
2022 Q4	$202K	Buy	+4,775	New	+$197K	0.01%	1070
2022 Q1	–	Sell	-423	Closed	-$16K	–	1452
2021 Q4	$16K	Buy	+423	New	+$17.6K	﹤0.01%	1395

Other funds holding GMAB

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Snowden Capital Advisors's GMAB Position: Q1 2026 in Review

Snowden Capital Advisors increased its Genmab (GMAB) stake by 28% in Q1 2026, buying an estimated $68.2K and bringing the position to 10,336 shares worth $277K. The position accounts for 0.01% of the portfolio, ranked #1066.

Snowden Capital Advisors first reported a position in GMAB in Q4 2021 and has held it in 9 quarters since. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

Snowden Capital Advisors held 10,336 shares of Genmab worth $277K as of Q1 2026.
Snowden Capital Advisors bought 2,275 Genmab shares in Q1 2026, an estimated $68.2K.
Genmab made up 0.01% of Snowden Capital Advisors's portfolio in Q1 2026, its #1066 holding.
Snowden Capital Advisors first reported a position in Genmab in Q4 2021 and has held it in 9 quarters since.
272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Snowden Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.